Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Trizuljak J, Sperr WR, Nekvindová L, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, Bonifacio M, Perkins C, Elena C, Malcovati L, Fortina AB, Shoumariyeh K, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, von Bubnoff N, Yavuz AS, Hägglund H, Mattsson M, Panse J, Jäkel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brockow K, Bretterklieber A, Niedoszytko M, van Anrooij B, Reiter A, Gotlib J, Kluin-Nelemans HC, Mayer J, Doubek M, Valent P. Trizuljak J, et al. Among authors: nekvindova l. Allergy. 2020 Aug;75(8):1927-1938. doi: 10.1111/all.14248. Epub 2020 Mar 16. Allergy. 2020. PMID: 32108361 Free PMC article.
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská A, Němcová L, Nekvindová L, Špaček M, Šimkovič M, Papajík T, Brejcha M, Lysák D, Zuchnická J, Novák J, Starostka D, Poul H, Vrbacký F, Vodárek P, Urbanová R, Plevová K, Pospíšilová Š, Mašlejová S, Brychtová Y, Koriťáková E, Smolej L, Doubek M. Panovská A, et al. Among authors: nekvindova l. Hematol Oncol. 2020 Oct;38(4):509-516. doi: 10.1002/hon.2744. Epub 2020 Jun 1. Hematol Oncol. 2020. PMID: 32400885
Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA.
Milota T, Hurnakova J, Pavelka K, Kristkova Z, Nekvindova L, Horvath R. Milota T, et al. Among authors: nekvindova l. Ther Adv Musculoskelet Dis. 2022 Mar 17;14:1759720X221081649. doi: 10.1177/1759720X221081649. eCollection 2022. Ther Adv Musculoskelet Dis. 2022. PMID: 35321118 Free PMC article.
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
Tužil J, Mlčoch T, Jirčíková J, Závada J, Nekvindová L, Svoboda M, Uher M, Křístková Z, Vencovský J, Pavelka K, Doležal T. Tužil J, et al. Among authors: nekvindova l. Expert Opin Biol Ther. 2020 Feb;20(2):183-192. doi: 10.1080/14712598.2020.1694900. Epub 2019 Nov 25. Expert Opin Biol Ther. 2020. PMID: 31736377
Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.
Mann HF, Závada J, Šenolt L, Bubová K, Nekvindová L, Křístková Z, Horák P, Vencovský J, Pavelka K; and the ATTRA Registry. Mann HF, et al. Among authors: nekvindova l. Clin Exp Rheumatol. 2019 Mar-Apr;37(2):342-343. Epub 2019 Jan 4. Clin Exp Rheumatol. 2019. PMID: 30620295 Free article. No abstract available.
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML. Michelsen B, et al. Among authors: nekvindova l. Arthritis Care Res (Hoboken). 2022 Jul;74(7):1205-1218. doi: 10.1002/acr.24560. Epub 2022 Apr 29. Arthritis Care Res (Hoboken). 2022. PMID: 33460531 Free article.
The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.
Skácelová M, Nekvindová L, Mann H, Závada J, Křístková Z, Vencovský J, Pavelka K, Horák P; ATTRA Registry. Skácelová M, et al. Among authors: nekvindova l. Rheumatol Int. 2022 May;42(5):803-814. doi: 10.1007/s00296-021-05072-2. Epub 2022 Mar 26. Rheumatol Int. 2022. PMID: 35338383 Free PMC article.
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Lindström U, Di Giuseppe D, Delcoigne B, Glintborg B, Möller B, Ciurea A, Pombo-Suarez M, Sanchez-Piedra C, Eklund K, Relas H, Gudbjornsson B, Love TJ, Jones GT, Codreanu C, Ionescu R, Nekvindova L, Závada J, Atas N, Yolbas S, Fagerli KM, Michelsen B, Rotar Ž, Tomšič M, Iannone F, Santos MJ, Avila-Ribeiro P, Ørnbjerg LM, Østergaard M, Jacobsson LT, Askling J, Nissen MJ. Lindström U, et al. Among authors: nekvindova l. Ann Rheum Dis. 2021 Nov;80(11):1410-1418. doi: 10.1136/annrheumdis-2021-220097. Epub 2021 Jun 3. Ann Rheum Dis. 2021. PMID: 34083206 Free PMC article.
15 results